



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 May 2017
EMA/CAT/393097/2017 Corr.
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 10-12 April 2017

Chair: Martina Schüßler-Lenz; Vice-Chair: Ilona Reischl

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.2.1.	Human autologous spheroids of matrix– associated chondrocytes for transplantation; EMA/H/C/0002736.....	5
2.3.	Day 180 list of outstanding issues	6
2.4.	Day 120 list of questions	6
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	6
2.7.	New applications	6
2.8.	Withdrawal of initial marking authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	7
2.11.1.	Imlygic - talimogene laherparepvec - EMA/H/C/002771/II/0008	7
2.12.	Other Post-Authorisation Activities	7
2.12.1.	Zalmoxis – Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δ Ingfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2); Orphan; EMA/H/C/002801/R/0003.....	7
3.	Certification of ATMPs	7
3.1.	Opinion.....	7
3.2.	Day 60 Evaluation Reports.....	7
3.3.	New Applications	8
4.	Scientific Recommendation on Classification of ATMPs	8
4.1.	New requests – Appointment of CAT Coordinator	8
4.1.1.	Autologous adipose derived mesenchymal stem cells; EMA/H0004813	8
4.1.2.	Mesenchymal stem cells isolated from umbilical cord; EMA/H0004815.....	8
4.1.3.	Bilayer, engineered, collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts; EMA/H0004817	8
4.1.4.	Replication incompetent adenoviral serotype 5 vector encoding the human interleukin-12 p70 (hIL-12) transgene under the control of the activator ligand, veledimex; EMA/H0004805 ...	8

4.1.5.	Adenovirus-associated viral vector serotype 5 containing CRISPR Cas9 and guide RNAs targeting intron 26 of the centrosomal protein 290 gene (AAV5-GRK1-SauCas9-CEP290gRNA 323/64); EMA/H0004818.....	9
4.1.6.	Autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (sTRAIL); EMA/H0004820.....	9
4.1.7.	Resorbable, viscoelastic matrix for use with autologous stromal vascular fraction (SVF); EMA/H0004819	9
4.1.8.	Allogeneic unexpanded amniotic fluid derived cells suspended with dried and cryofractured amniotic tissue; EMA/H0004816	9
4.1.9.	Human autologous stromal vascular fraction (SVF); EMA/H0004822	9
4.1.10.	Human autologous adipose-derived stromal/stem cells (ADSCs); EMA/H0004823.....	10
4.2.	Day 30 ATMP scientific recommendation	10
4.2.1.	Human induced pluripotent stem cell derived natural killer cells expressing high-affinity non-cleavable CD16 Fc; EMA/H0004784	10
4.2.2.	Autologous cultured Wharton jelly derived mesenchymal stem cells; EMA/H0004795	10
4.2.3.	Allogeneic cultured Wharton jelly derived mesenchymal stem cells; EMA/H0004796	10
4.2.4.	Autologous cultured adipose regenerative mesenchymal stem cells; EMA/H0004797.....	10
4.2.5.	Autologous adipose derived mesenchymal stem cells; EMA/H0004798	11
4.2.6.	Autologous cultured adipose derived mesenchymal stem cells - EMA/H0004799	11
4.3.	Day 60 revised scientific recommendation (following list of questions)	11
4.3.1.	Stimulated resistant cells suspension cancer vaccine; H0004763/0001	11
4.4.	Finalisation of procedure	11
4.4.1.	Allogenic human mesenchymal stem cells - mesenchymal stem cells, umbilical cord derived; EMA/H0004758/0001	11
4.4.2.	Recombinant adeno-associated virus serotype 8 (rAAV8) thyroxine-binding globulin (TBG) human uridine diphosphate glucuronosyltransferase 1A1 (hUGT1A1); EMA/H0004757/000112	
4.4.3.	Autologous human mesenchymal stem cells - mesenchymal stem cells, bone marrow derived; EMA/H0004766/0001	12
4.4.4.	Banked allogenic leukocytes - Leukocytes with high cancer killing activity (CKA); EMA/H0004785/0001	12
4.4.5.	Implantable continuous glucose monitoring system; EMA/H0004762/0001	12
4.4.6.	Oncolytic adenovirus; EMA/H0004767	12
4.5.	Follow-up and guidance.....	12
5.	Scientific Advice	13
5.1.	New requests – appointment of CAT Coordinators.....	13
5.2.	CAT reports.....	13
5.3.	List of Issues	13
5.4.	Finalisation of SA procedures	13
6.	Pre-Authorisation Activities	13
6.1.	Paediatric investigation plans.....	13
6.2.	ITF briefing meetings in the field of ATMPs	13

6.3.	Priority Medicines (PRIME) – Eligibility requests	13
6.3.1.	Month 0 - Start of the procedure	13
6.3.2.	Month 1 – Discussion of eligibility	13
6.3.3.	Month 2 – Recommendation of eligibility.....	13
6.3.4.	Month 3 – Nomination of Rapporteurs	13
6.3.5.	Ongoing support.....	13
7.	Organisational, regulatory and methodological matters	14
7.1.	Mandate and organisation of the CAT	14
7.1.1.	Strategic Review & Learning meeting – Malta, June 2017	14
7.1.2.	CAT - Best practice guide	14
7.1.3.	Good manufacturing practice (GMP) requirements for ATMPs	14
7.1.4.	CAT meeting dates 2019 - 2021	14
7.2.	Coordination with EMA Scientific Committees	14
7.2.1.	Procedural advice on the evaluation of advanced therapy medicinal products	14
7.2.2.	Committee for Medicinal Products for Human Use (CHMP)	15
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	15
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP)	15
7.3.2.	Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)	15
7.3.3.	Guideline on quality, non-clinical and clinical aspects of gene therapy medicinal products .	15
7.4.	Cooperation within the EU regulatory network	16
7.4.1.	Orphan similarity for ATMPs	16
7.5.	Cooperation with international regulators	16
7.6.	CAT work plan	16
7.6.1.	CAT 2017 work plan.....	16
7.6.2.	Development of non-substantially manipulated cell-based ATMPs: flexibilities introduced via the application of the risk-based approach (previously called: ‘Questions and Answers document on minimally manipulated ATMPs’)	16
7.7.	Planning and reporting	17
7.8.	Others	17
8.	Any other business	17
9.	Explanatory notes	18
10.	List of participants	22

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The CAT chair welcomed the new member from Cyprus (Marian Ieridi) who attended the CAT for the first time.

1.2. Adoption of agenda

The CAT agenda for 10-12 April 2017 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 15-17 March meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

2.2.1. Human autologous spheroids of matrix-associated chondrocytes for transplantation - EMA/H/C/0002736

Claimed indication: repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee (International Cartilage Repair Society [ICRS] grade III or IV) with defect sizes up to 10 cm² in adults

Scope: Oral explanation

Action: Oral explanation held on 11 April 2017 from 09:30hrs

List of Outstanding Issues adopted on 17.02.2017. List of Questions adopted on 19.04.2013

The Rapporteur and CoRapporteur presented their assessment of the responses from the applicant to the list of outstanding issues. CAT was also informed of the outcome of the BWP discussion. During the oral explanation (OE), the applicant presented their responses. The CHMP chair and the CHMP coordinators from the Rapporteur and CoRapporteur teams attended the OE via teleconference. The applicant addressed questions from the CAT and CHMP members.

A trend vote was taken

The outcome of the trend vote is a recommendation by CAT, by majority, to grant a full marketing authorisation. The final vote will be taken at the May 2017 CAT meeting. Divergent views will be prepared.

CAT discussed and adopted a further list of outstanding issues.

Finally a discussion took place on the standard term.

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0008

Amgen Europe B.V.

Rapporteur: Olli Tenhunen; CHMP Coordinator: Tuomo Lapveteläinen

Scope: Quality

Action: for adoption

CAT adopted by consensus the opinion for this type II variation.

2.12. Other Post-Authorisation Activities

Annex C - Post-Authorisation Measures (PAMs): Line listing of ATMPs post authorisation measures with procedures starting in April 2017 will be tabled in CAT MMD two weeks after current CAT meeting

Annex D - Post-Authorisation Measures (PAMs): Line listing of ATMPs post authorisation measures with procedures concluded in April 2017 will be tabled in CAT MMD two weeks after current CAT meeting

2.12.1. Zalmoxis – Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δ l η ngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2) – Orphan - EMEA/H/C/002801/R/0003

MolMed SpA; Treatment of adjunctive treatment in haploidentical haematopoietic stem cell transplantation of adult patients with high-risk haematological malignancies

Rapporteur: Hans Ovelgönne; CHMP Coordinator: Paula Boudewina van Hennik; PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: 1st annual reassessment for renewal of conditional MA. Opinion

Action: for adoption

CAT adopted the request for supplementary information.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous adipose derived mesenchymal stem cells; EMA/H0004813

Intended for the treatment of chronic wound

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.2. Mesenchymal stem cells isolated from umbilical cord; EMA/H0004815

Intended for the treatment of chronic obstructive pulmonary disease

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.3. Bilayer, engineered, collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts; EMA/H0004817

Intended for the treatment of partial deep dermal and full thickness burn wounds

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.4. Replication incompetent adenoviral serotype 5 vector encoding the human interleukin-12 p70 (hIL-12) transgene under the control of the activator ligand, veledimex; EMA/H0004805

Intended for the treatment of recurrent or progressive glioblastoma

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.5. [Adenovirus-associated viral vector serotype 5 containing CRISPR Cas9 and guide RNAs targeting intron 26 of the centrosomal protein 290 gene \(AAV5-GRK1-SauCas9-CEP290gRNA 323/64\); EMA/H0004818](#)

Intended for the treatment of patients aged 3 years and older with Leber congenital amaurosis type 10 (LCA10) caused by a homozygous or compound heterozygous intron 26 mutation, c.2991+1655 A>G, in the CEP290 gene

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.6. [Autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand \(sTRAIL\); EMA/H0004820](#)

Intended for the treatment of TRAIL-sensitive cancers such as Ewing sarcoma and pancreatic ductal adenocarcinoma

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.7. [Resorbable, viscoelastic matrix for use with autologous stromal vascular fraction \(SVF\); EMA/H0004819](#)

A resorbable matrix to be used for the delivery of autologous SVF adipose derived cells for the treatment of human immunodeficiency virus (HIV)-related facial lipoatrophy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.8. [Allogeneic unexpanded amniotic fluid derived cells suspended with dried and cryofractured amniotic tissue; EMA/H0004816](#)

Intended for the treatment of chronic wound care

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.9. [Human autologous stromal vascular fraction \(SVF\); EMA/H0004822](#)

Intended for the treatment of articular cartilage and bone defects

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.1.10. Human autologous adipose-derived stromal/stem cells (ADSCs); EMA/H0004823

Intended for the treatment of articular cartilage and bone defects

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Nominations were received. The CAT member was appointed as CAT coordinator for this procedure.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Human induced pluripotent stem cell derived natural killer cells expressing high-affinity non-cleavable CD16 Fc; EMA/H0004784

Intended for the treatment of advanced solid tumour malignancies

Scope: scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 2 May 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.2. Autologous cultured Wharton jelly derived mesenchymal stem cells; EMA/H0004795

Intended for the treatment of amyotrophic lateral sclerosis or other central or peripheral nervous system repair

Scope: scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT decided to request some additional information from the applicant before concluding on this classification request.

4.2.3. Allogeneic cultured Wharton jelly derived mesenchymal stem cells; EMA/H0004796

Intended for the treatment of amyotrophic lateral sclerosis or other central or peripheral nervous system repair

Scope: scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT decided to request some additional information from the applicant before concluding on this classification request.

4.2.4. Autologous cultured adipose regenerative mesenchymal stem cells; EMA/H0004797

Intended for the treatment of autoimmune epilepsy and other central or peripheral nervous system repair

Scope: scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT decided to request some additional information from the applicant before concluding on this classification request.

4.2.5. [Autologous adipose derived mesenchymal stem cells; EMA/H0004798](#)

Intended for the treatment of autoimmune epilepsy and other central or peripheral nervous system repair

Scope: scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT decided to request some additional information from the applicant before concluding on this classification request.

4.2.6. [Autologous cultured adipose derived mesenchymal stem cells - EMA/H0004799](#)

Intended for the treatment of autoimmune epilepsy and other central or peripheral nervous system repair

Scope: scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT decided to request some additional information from the applicant before concluding on this classification request.

4.3. **Day 60 revised scientific recommendation (following list of questions)**

4.3.1. [Stimulated resistant cells suspension cancer vaccine; H0004763/0001](#)

Intended for colorectal cancer

Scope: revised scientific recommendation

Action: for adoption

CAT discussed the revised ATMP classification report. CAT adopted by consensus the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 2 May 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.4. **Finalisation of procedure**

4.4.1. [Allogenic human mesenchymal stem cells - mesenchymal stem cells, umbilical cord derived; EMA/H0004758/0001](#)

Intended for intervertebral disc regeneration

Scope: No comments raised by the European Commission

Action: for information

The CAT noted this information.

4.4.2. [Recombinant adeno-associated virus serotype 8 \(rAAV8\) thyroxine-binding globulin \(TBG\) human uridine diphosphate glucuronosyltransferase 1A1 \(hUGT1A1\); EMA/H0004757/0001](#)

Intended for the treatment of Crigler-Najjar (CN) syndrome

Scope: No comments raised by the European Commission

Action: for information

The CAT noted this information.

4.4.3. [Autologous human mesenchymal stem cells - mesenchymal stem cells, bone marrow derived; EMA/H0004766/0001](#)

Intended for the treatment of coma (brain injury, stroke)

Scope: No comments raised by the European Commission

Action: for information

The CAT noted this information.

4.4.4. [Banked allogenic leukocytes - Leukocytes with high cancer killing activity \(CKA\); EMA/H0004785/0001](#)

Intended for the treatment of metastatic pancreatic ductal adeno carcinoma

Scope: No comments raised by the European Commission

Action: for information

The CAT noted this information.

4.4.5. [Implantable continuous glucose monitoring system; EMA/H0004762/0001](#)

Intended for the treatment of adjunct glucose monitoring in diabetes patients

Scope: No comments raised by the European Commission

Action: for information

The CAT noted this information.

4.4.6. [Oncolytic adenovirus; EMA/H0004767](#)

Intended for the treatment of pancreatic cancer

Scope: scientific recommendation

Scope: No comments raised by the European Commission

Action: for information

The CAT noted this information.

4.5. Follow-up and guidance

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Rapporteurs

5.2. CAT reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Month 3 – Nomination of Rapporteurs

6.3.5. Ongoing support

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Strategic Review & Learning meeting – Malta, June 2017

CAT Strategic Review & Learning meeting (SRLM) will take place in Gozo, Malta on 1-2 June 2017 under the auspices of the Maltese Presidency of the Council of the European Union

CAT: John-Joseph Borg

Scope: draft programme

Action: for information

The CAT noted this information.

7.1.2. CAT - Best practice guide

CAT: Martina Schübler-Lenz

Scope: Proposal for a best practice guide

Action: for discussion

CAT discussed the proposal for a best practice guide. The document was considered useful. CAT secretariat to organise a refresher training on how to access MMD and the CAT Eudrabox for CAT members/alternates that are not part of national competent authorities.

7.1.3. Guideline on good manufacturing practice for advanced therapy medicinal products

CAT: Martina Schübler-Lenz

Scope: proposed way forward.

Action: for information

The CAT chair provided information on the next steps to discuss and finalise the GMP for ATMP guideline.

7.1.4. CAT meeting dates 2019 - 2021

Scope: meeting dates for 2019 – 2021

Action: for adoption

The meeting dates were adopted.

7.2. Coordination with EMA Scientific Committees

7.2.1. Procedural advice on the evaluation of advanced therapy medicinal products

Scope: revised document for presentation to Committees

Action: for discussion

EMA presented the change introduced in the procedural advice to further clarify the roles of the CAT, CHMP and PRAC during the initial evaluation and re-examination of MAAs for ATMPs.

The procedural advice will now be presented to CHMP and PRAC. Comments from committee members are expected by end of June 2017. The document will be finalised and adopted in September 2017.

7.2.2. [Committee for Medicinal Products for Human Use \(CHMP\)](#)

Scope: Summary of Outcomes (SoO) for the 15-17 March 2017 meeting

Action: for information

The CAT noted this information.

7.3. [Coordination with EMA Working Parties/Working Groups/Drafting Groups](#)

7.3.1. [Working Party with Patients' and Consumers' Organisations \(PCWP\)](#)

Scope: minutes of the PCWP with all eligible organisations that took place on 30 November 2016

Action: for information

The CAT noted this information.

7.3.2. [Working Party with Patients' and Consumers' Organisations \(PCWP\) and Working Party with Healthcare Professionals' Organisations \(HCPWP\)](#)

Scope: agenda of the workshop on personalised medicines: role of patients, consumers and healthcare professionals, 14 March 2017 and agenda of the PCWP/HCPWP joint meeting, 15 March 2017

Action: for information

The CAT noted this information.

7.3.3. [Guideline on quality, non-clinical and clinical aspects of gene therapy medicinal products](#)

Scope: Drafting group will take place on 10 May 2017 from 10:00-13:30hrs to finalise the revision. Call for interest for additional CAT members to join the drafting group

Action: for discussion

Drafting group composition:

-Quality: M. Menezes-Ferreira, C. Niederlaender, S. Ruiz and P. Salmikangas

-Non-clinical: K. Breen, B. Sarkadi, M. Renner

-Clinical: P. Gasparini, B. Klug, M. Hystad, O. Tenhunen

CAT members interested to join this drafting group meeting should inform the CAT secretariat. Bernd Gänsbacher will attend.

7.4. Cooperation within the EU regulatory network

7.4.1. Orphan similarity for ATMPs

CAT drafting group: Simona Badoi, Violaine Closson-Carella, Michele Lipucci, Martina Menezes-Ferreira, Christiane Niederlaender, Ilona Reischl, Paula Salmikangas

Scope: Reflection from the perspective of ATMPs on the concept of 'similar active substance' as referred to in Art 3(3)c of Reg (EC) No 847/2000 of April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concept 'similar medicinal product' and 'clinical superiority'. Review of comments received from the public consultation. Feedback from the breakout meeting that will take place on Monday 10 April 2017

Action: for information

Timeline:

-Break out meeting organised for Monday 10 April 2017

Consultation document published by the European Commission

http://ec.europa.eu/health/sites/health/files/files/orphanmp/2016_07_pc_orphan/2016_07_consultation_paper.pdf

Feedback was provided from the discussions in the break-out meeting of 10 April 2017.

7.5. Cooperation with international regulators

None

7.6. CAT work plan

7.6.1. CAT 2017 work plan

Scope: Work plan was adopted via written procedure on 22 March 2017

Action: for information

CAT proposed some changes to the document and appointed additional CAT topic leaders. The document was subsequently readopted.

7.6.2. Development of non-substantially manipulated cell-based ATMPs: flexibilities introduced via the application of the risk-based approach (previously called: 'Questions and Answers document on minimally manipulated ATMPs')

Scope: draft document

Action: for adoption

The final version of the document was presented. The changes introduced following the comments from the CAT members were endorsed. One amendment was made to section 3.3. The document was subsequently adopted.

In view of the aim and outline of the document (as an example: how to apply the Guideline on a risk-based approach), CAT decided that there was no value of publishing this paper for external consultation. CAT secretariat will proceed with the publication of the final CAT document.

7.7. Planning and reporting

None

7.8. Others

8. Any other business

No items

Date of next CAT meeting:

10-12/05/2017

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOIs: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices
SAG-O: Scientific Advisory Group Oncology
SAWP: Scientific Advice Working Party
SR: Summary Report
SWP: Scientific Working Party
SME: Small and medium size enterprises
SmPC: Summary of Products Characteristics
TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (*section 2.9*) and Post-authorisation activities (*section 2.10*).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (*section 2.3*) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue

for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 10-12 April 2017 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Ilona Reischl	Member	Austria	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Ivica Malnar	Alternate	Croatia	No interests declared	
Marina Ieridi	Member	Cyprus	No interests declared	
Tomáš Boráň	Member	Czech Republic	No interests declared	
Nanna Aaby Kruse	Member	Denmark	No restrictions applicable to this meeting	
Toivo Maimets	Member	Estonia	No interests declared	
Paula Salmikangas	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Jan Mueller-Berghaus	Alternate	Germany	No interests declared	
Egbert Flory	Alternate	Germany	No interests declared	
Angeliki Roboti	Alternate	Greece	No interests declared	
Krisztian Fodor	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Paolo Gasparini	Member	Italy	No interests declared	
Una Riekstina	Member	Latvia	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Johannes Hendrikus Ovelgönne	Member	Netherlands	No interests declared	
Rune Kjeklen	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Simona Badoi	Member	Romania	No interests declared	
Mikuláš Hrubíško	Member	Slovakia	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
			applicable to this meeting	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lennart Åkerblom	Member	Sweden	No interests declared	
Björn Carlsson	Alternate	Sweden	No interests declared	
Marc Turner	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	
Mariëtte Driessens	Member	Patients' Representative	No restrictions applicable to this meeting	
Erik Briers	Alternate	Patients' Representative	No restrictions applicable to this meeting	
Christos Sotirelis	Expert - in person*	Eurordis	No interests declared	
Mari Martikainen	Expert - in person*	Finland	No interests declared	
Heli Suila	Expert - in person*	Finland	No interests declared	
Guido Panté	Expert - in person*	Italy	No interests declared	
Carla Herberts	Expert - in person*	Netherlands	No interests declared	
Monique Wakelkamp	Expert - in person*	Sweden	No interests declared	
Tomas Salmonson	Expert - via telephone*	Sweden	No interests declared	
Kristina Dunder	Expert - via telephone*	Sweden	No interests declared	
Tuomo Lapveteläinen	Expert - via telephone*	Finland	No interests declared	
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.